Internal medicine (Tokyo, Japan)
Tumor Inflammation-Associated Neurotoxicity Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy In A Patient With High-Grade B-Cell Lymphoma.
Kenjiro Hino, Taro Edahiro, Tsuyoshi Muta, Hiroshi Ureshino, Suzuka Nakatani, Takuya Nunomura, Takeshi Okatani, Nao Yoshida, Ren Chishaki, Tetsumi Yoshida, Takero Shindo, Tatsuo Ichinohe
Published: 202510.2169/internalmedicine.6077-25
Abstract
A 41-year-old man with high-grade B-cell lymphoma developed neurolymphomatosis (NL) after frontline chemotherapy. He received CD19 CAR T-cell therapy (lisocabtagene maraleucel) and subsequently developed tumor inflammation-associated neurotoxicity (T…
Preview only. Read the full abstract at the source